Literature DB >> 3533593

Inflammation: a two-edged sword--the model of bronchiectasis.

P J Cole.   

Abstract

A short-lived, controlled inflammatory response by the host is required to protect against incursions by foreign material into the upper and lower respiratory tract. If this response fails to eliminate the aggressor, inflammation is amplified and becomes chronic in an attempt to rectify the situation. This unsuccessful response is poorly controlled and caused damage to surrounding normal tissue, leading to progressive disease. Hence, inflammation can be helpful or harmful--a two-edged sword. Chronic bronchial sepsis, of which bronchiectasis is an example, and chronic sinusitis display the hallmarks of this 'vicious circle' of host-mediated, inflammatory tissue damage and provide a useful model in man in which to ask questions, the answers to which provide valuable information about the pathogenesis of chronic inflammatory disease of the lung.

Entities:  

Mesh:

Year:  1986        PMID: 3533593

Source DB:  PubMed          Journal:  Eur J Respir Dis Suppl        ISSN: 0106-4347


  138 in total

1.  Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors.

Authors:  J Angrill; C Agustí; R de Celis; A Rañó; J Gonzalez; T Solé; A Xaubet; R Rodriguez-Roisin; A Torres
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  Bronchiectasis exacerbations: The role of atypical bacteria, respiratory syncytial virus and pulmonary function tests.

Authors:  Eugenios I Metaxas; Evangelos Balis; Joseph Papaparaskevas; Nicholas Spanakis; Georgios Tatsis; Athanasios Tsakris
Journal:  Can Respir J       Date:  2015-04-15       Impact factor: 2.409

Review 3.  Medical management of bronchiectasis.

Authors:  Anne E O'Donnell
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 4.  Surgical management of non-cystic fibrosis bronchiectasis.

Authors:  Miyako Hiramatsu; Yuji Shiraishi
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

5.  Inhaled fluticasone in bronchiectasis: a 12 month study.

Authors:  K W Tsang; K C Tan; P L Ho; G C Ooi; J C Ho; J Mak; G L Tipoe; C Ko; C Yan; W K Lam; M Chan-Yeung
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

Review 6.  Treatment of bronchiectasis in adults.

Authors:  Nick H T ten Hacken; Peter J Wijkstra; Huib A M Kerstjens
Journal:  BMJ       Date:  2007-11-24

Review 7.  Interventions for bronchiectasis: an overview of Cochrane systematic reviews.

Authors:  Emma J Welsh; David J Evans; Stephen J Fowler; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

Review 8.  Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways.

Authors:  Sanjay H Chotirmall; Maria Teresa Martin-Gomez
Journal:  Mycopathologia       Date:  2017-05-17       Impact factor: 2.574

9.  Advantages and drawbacks of long-term macrolide use in the treatment of non-cystic fibrosis bronchiectasis.

Authors:  Li-Chao Fan; Jin-Fu Xu
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

10.  Deletion of airway cilia results in noninflammatory bronchiectasis and hyperreactive airways.

Authors:  Sandra K Gilley; Antine E Stenbit; Raymond C Pasek; Kelli M Sas; Stacy L Steele; May Amria; Marlene A Bunni; Kimberly P Estell; Lisa M Schwiebert; Patrick Flume; Monika Gooz; Courtney J Haycraft; Bradley K Yoder; Caroline Miller; Jacqueline A Pavlik; Grant A Turner; Joseph H Sisson; P Darwin Bell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-08       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.